Followers | 145 |
Posts | 27568 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, May 12, 2021 12:43:53 PM
https://www.markets.co/oppenheimer-releases-a-buy-rating-on-gamida-cell-gmda/316897/
May 11, 2021 Christine Brown Healthcare
In a report released yesterday, Mark Breidenbach from Oppenheimer assigned a Buy rating to Gamida Cell (GMDA – Research Report), with a price target of $17.00. The company’s shares closed last Tuesday at $6.84.
Recent GMDAQ News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 08:01:05 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/14/2024 04:15:25 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/10/2024 08:19:25 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/09/2024 08:08:28 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/09/2024 08:04:39 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM